Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment

被引：2
|
作者：
Provencio, M.
Cobo, M.
Vazquez-Estevez, S.
Firvida, J.
Macia, S.
Barneto, I.
Oramas, J.
Sanchez-Hernandez, A.
Ferrer, N.
Paredes, A.
机构：
[1] Hosp Puerta de Hierro, Madrid, Spain
[2] Hosp Univ Carlos Haya, Malaga, Spain
[3] Complexo Xeral Calde, Lugo, Spain
[4] Complexo Hosp Ourense, Orense, Spain
[5] Hosp Gen Elda, Elda, Spain
[6] Hosp Univ Reina Sofia, Dept Clin Oncol, Cordoba, Spain
[7] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[8] Hosp Prov Castellon, Castellon de La Plana, Spain
[9] Hosp Son Llatzer, Palma De Mallorca, Spain
[10] Hosp Donostia, San Sebastian, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18109
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer
    Di Maio, Massimo
    Morabito, Alessandro
    Daniele, Gennaro
    Giordano, Pasqualina
    Piccirillo, Maria Carmela
    Costanzo, Raffaele
    Sandomenico, Claudia
    Montanino, Agnese
    Gridelli, Cesare
    Rocco, Gaetano
    Perrone, Francesco
    LUNG CANCER MANAGEMENT, 2012, 1 (01) : 55 - 62
  • [22] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [23] Second-line treatment options in advanced non-small cell lung cancer: Current status
    Cullen, M
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S3 - S8
  • [24] Postprogression Survival in Patients With Advanced Non-Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy
    Hayashi, Hidetoshi
    Okamoto, Isamu
    Taguri, Masataka
    Morita, Satoshi
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2013, 14 (03) : 261 - 266
  • [25] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [26] Smoking and prognostic factors in advanced non-small cell lung cancer (NSCLC)
    Altug, S.
    Li, C.
    Marek, M.
    Guclu, S.
    Kim, Y.
    Meshref, M.
    Qin, S.
    Krejcy, K.
    Reece, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
    Ondhia, Umang
    Conter, H. J.
    Owen, Scott
    Zhou, Anna
    Nam, Julian
    Singh, Sumeet
    Abdulla, Ahmed
    Chu, Paula
    Felizzi, Federico
    Paracha, Noman
    Sanghag, Randeep
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (07) : 625 - 637
  • [28] FREQUENCY OF SECOND-LINE CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Suzuki, Kensuke
    Kenmotsu, Hirotsugu
    Taira, Tetsuhiko
    Naito, Tateaki
    Kimura, Madoka
    Hisamatsu, Yasushi
    Tokito, Takaaki
    Imai, Hisao
    Akamatsu, Hiroaki
    Ono, Akira
    Shukuya, Takehito
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S484 - S484
  • [29] Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer
    Sanchez Escudero, Laura
    Cobelas Cartagena, Stephanie S.
    Sanchez Esperilla, Maria
    Bayo, Juan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Predictors and impacts of second-line chemotherapy on survival after progression in patients with advanced non-small cell lung cancer (NSCLC)
    Teramukai, S.
    Nishimura, T.
    Nakagawa, M.
    Kawahara, M.
    Kubota, K.
    Furuse, K.
    Fukushima, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345